Allergy Immunotherapy: The Only Disease-Modifying Treatment

Written by Empire Medical Training Editorial Team

Medically reviewed by Sherry Wehner, MD Board-Certified Pathologist & Dermatopathologist; Aesthetic & Wellness Medicine

Updated June 2026 ·10 min read

Allergy immunotherapy occupies a unique place in allergy care. Nearly every other treatment a patient with allergic rhinitis, conjunctivitis, or environmental allergies is offered — antihistamines, nasal corticosteroids, leukotriene modifiers, decongestants — works by suppressing the allergic response. They blunt symptoms, but the day a patient stops taking them, the allergy is exactly as it was. Immunotherapy is the one treatment that changes the disease itself. By delivering the offending allergens in gradually increasing amounts, it retrains the immune system toward tolerance, which is why it is correctly described as the only disease-modifying allergy treatment.

This guide is part of Empire's Allergy Testing & Treatment resource cluster and is written for clinicians. It is clinical education, not medical advice, and nothing here is a treatment protocol, dosing schedule, or substitute for proper training and current standards of care.

What allergy immunotherapy is — and why it's unique

As Dr. Sherry Wehner frames it in Empire's course, patients call these “allergy shots,” but they are more accurately understood as desensitizing treatment. The mechanism runs straight through the allergic cascade: in a sensitized patient, allergen binds IgE on mast cells, triggering degranulation and the release of histamine and other mediators that produce the itching, redness, and swelling of allergic disease. Immunotherapy intervenes upstream. Repeated, controlled exposure to the allergen drives the immune system to build tolerance — shifting antibody and regulatory responses so that the same allergen no longer provokes the same reaction.

The honest clinical framing matters here. Immunotherapy is not a cure. What it reliably does, as Wehner puts it, is greatly decrease symptoms and improve quality of life. The payoff can be dramatic: a patient who has suffered for years from severe, debilitating seasonal allergies can, after a sustained course of treatment, return to a relatively normal life. That is what makes immunotherapy the most rewarding part of allergy care for both the clinician and the patient — and what separates it from every medication that merely manages symptoms week to week.

Subcutaneous immunotherapy (SCIT): the allergy shot

Subcutaneous immunotherapy — SCIT, the conventional “allergy shot” — is the well-established, evidence-backed route and the one most providers build their program around. The injection itself is simple: a subcutaneous shot in the posterior or lateral forearm. If a patient is receiving two allergen mixes that day, they get one in each arm. The discipline is in the schedule and the safety, not the injection.

SCIT is delivered in two phases:

• Build-up phase. The patient comes in roughly one to three times per week while the dose is escalated step by step. They start at a highly diluted concentration and move up — increasing the amount at each visit, then stepping to a more concentrated vial and dropping back down on volume before climbing again — until they reach the target maintenance dose. The exact escalation schedule is built around the specific vials prepared for that patient and is taught in Empire's course.
• Maintenance phase. Once the target dose is reached, visits drop to roughly once every two to four weeks, tailored to the patient's schedule and availability.

Two operating rules govern the schedule. First, never skip a dose: if a patient misses visits, you stay on the same schedule and simply take longer to work through the dosing — you don't leap ahead. Second, dosing is not reduced during high allergy seasons; there is no data supporting that practice. SCIT works for environmental allergens; it is not used for food allergies or contact allergies, where avoidance is the strategy — see food allergies vs. food sensitivities.

Most providers do not mix their own immunoserums when starting out. As Wehner advises — the same way she uses a compounding pharmacist for medications — she uses a certified allergy lab to prepare patient-specific vials. The lab navigates the real technical difficulties: cross-reactivity (where one antigen can cover several related ones), the fact that some antigens cannot be mixed together, and stepped dosing where certain allergens are introduced only later. Mixing your own is possible and carries higher reimbursement, but it requires additional training. How to work with an allergy lab is covered on setting up an allergy lab.

Sublingual immunotherapy (SLIT): the at-home route

Sublingual immunotherapy — SLIT — delivers the allergen as drops or tablets under the tongue, which the patient can take at home. Its appeal is convenience: no weekly office visits and no needles. The trade-offs are real and worth stating plainly. SLIT is generally less effective than SCIT, and the at-home drops are typically not covered by insurance. The picture is not uniform, though: FDA-approved SLIT tablets exist for specific allergens (grass, ragweed, and dust mite), and these stand on a firmer regulatory and evidence footing than compounded sublingual drops, which are largely off-label.

For the full comparison — convenience versus efficacy, coverage, candidacy, and how to position SLIT for the patient who simply cannot make weekly visits — see the dedicated sublingual immunotherapy guide.

Who is a candidate

Immunotherapy is for the patient whose environmental allergies are confirmed and meaningfully affecting their life, not for anyone with a runny nose. The practical gate, anchored in how coverage works, is three or more positive environmental allergens on testing — for skin-prick testing, a wheal at least 3 mm larger than the negative control. Patients with one or two positive results (most often house dust mite or cat) are usually counseled on avoidance first; some still elect immunotherapy out of pocket when avoidance isn't realistic, for example when they won't part with a pet.

Good candidacy generally means:

• Multiple confirmed environmental sensitizations documented by skin testing or specific-IgE blood testing, correlated with the patient's clinical history.
• Inadequate response to avoidance and medications — the patient who is still symptomatic despite antihistamines and nasal steroids is exactly who benefits most.
• Symptomatic allergic rhinitis, conjunctivitis, or other manifestations of environmental allergies driven by those confirmed sensitizations.

Equally important is who is not a routine candidate for an office-based program. A patient with a history of anaphylaxis is a more complex case better referred to a board-certified allergist or immunologist, and immunotherapy is not appropriate in uncontrolled asthma — an asthma flare during treatment is dangerous, and these patients also belong with a specialist. Immunotherapy does not treat food or contact allergy. Knowing which patients to keep and which to refer is a core skill, and it is taught explicitly in Empire's course.

Time course, durability, and realistic expectations

Patients deserve an honest answer to “how long will this take, and what will it do for me?” before they commit. Immunotherapy is a long-term commitment, not a quick fix. Symptom improvement builds gradually over the first year, and a full course of SCIT generally runs several years to produce durable tolerance — after which many patients retain lasting benefit even once treatment stops, the hallmark of a disease-modifying therapy. At the end of a treatment cycle the patient is retested; if positive results persist, a new patient-specific prescription can be ordered to continue.

Set expectations accordingly. The realistic promise is substantially reduced symptoms and a better quality of life, not a cure or zero reactivity. Framing this honestly up front is also what keeps patients on schedule — the single biggest threat to outcomes is dropout. The most common reason patients start missing doses is mundane: the required 30-minute in-office observation after each injection gets tedious. Telling them about the commitment, the time course, and that observation window before they begin earns the persistence the treatment requires.

Safety: systemic reactions, anaphylaxis, and emergency readiness

Immunotherapy is deliberately giving a sensitized patient the very allergens they react to, so safety is not optional — it is the foundation of the program. In practice, immunotherapy injections are very safe: across thousands of injections in Wehner's clinic, and among colleagues she's spoken with, severe reactions have not occurred. But systemic reactions and anaphylaxis are possible, and the entire workflow is built to catch and treat them.

Several disciplines are non-negotiable:

• Post-injection observation. Every patient stays in the office at least 30 minutes after each shot so staff can watch for a systemic reaction — the window when one would declare itself.
• Emergency readiness, always. Epinephrine must be on hand. Wehner prescribes patients two EpiPens at the consultation and requires them to bring their own to every visit — no EpiPen, no injection that day — so the clinic's in-house supply stays reserved for true emergencies. (The two-pack ships with a trainer injector: “blue to the sky, orange to the thigh.”) Over-the-counter hydrocortisone cream and oral diphenhydramine handle the typical minor local reaction of redness and itching.
• Step back, don't stop. A reaction — local, or systemic with congestion, rhinitis, or difficulty breathing — does not mean abandoning treatment. You drop to the last dose that didn't cause a reaction, then resume the normal climb; if it recurs, step down again. A certified allergy lab will supply extra immunoserums to cover the repeated steps.
• Not for uncontrolled asthma. These patients carry real risk during treatment and belong with a board-certified specialist.

Anaphylaxis is a medical emergency whose first-line treatment is intramuscular epinephrine. The exact emergency response, dosing, and the full reaction-management algorithm are taught in depth in Empire's course — a clinician offering immunotherapy must have that training, the right setting, and the supplies in place before the first injection.

Adding immunotherapy to your practice

Immunotherapy is where allergy care becomes both clinically rewarding and a meaningful revenue line. Roughly one in five patients who get tested qualify for immunotherapy, and injectable immunotherapy carries substantially higher reimbursement than testing alone — it is usually covered by insurance when the patient has three or more positive environmental skin-prick results. The realistic way to start, Wehner's own model, is to partner with a certified, full-service allergy lab that prepares the patient-specific vials, provides supplies, and supports correct billing and coding — rather than mixing your own immunoserums on day one.

Because allergy affects more than 56 million Americans while there are fewer than 6,000 board-certified allergists in the country, the unmet need is enormous — a genuine opportunity for trained clinicians outside that specialty to help patients and grow their practice. You do not have to be board-certified in allergy and immunology to test patients and provide immunotherapy. The operational side — lab partnership, documentation, and the billing and coding that determines whether you're actually reimbursed for the work — is covered in how to add allergy testing to your practice and taught end-to-end in Empire's training.